| Year |
Citation |
Score |
| 2015 |
Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America. PMID 26508629 DOI: 10.1073/Pnas.1516853112 |
0.305 |
|
| 2015 |
Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discovery. PMID 26286086 DOI: 10.1158/2159-8290.Cd-15-0654 |
0.416 |
|
| 2014 |
Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery. 4: 1046-61. PMID 24893891 DOI: 10.1158/2159-8290.Cd-14-0337 |
0.38 |
|
| 2013 |
Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: E3595-604. PMID 24019492 DOI: 10.1073/Pnas.1220050110 |
0.453 |
|
| 2013 |
Red Brewer M, Pao W. Maximizing the benefits of off-target kinase inhibitor activity. Cancer Discovery. 3: 138-40. PMID 23400472 DOI: 10.1158/2159-8290.Cd-12-0581 |
0.367 |
|
| Show low-probability matches. |